#080: B-Cell Depletion – Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) for active RRMS and SPMS, and early PPMS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#270: Alemtuzumab (Lemtrada, Campath) bei hochaktiver Multipler Sklerose
Alemtuzumab (Lemtrada, Campath) is a DMT to treat highly active MS and has long-lasting effects and potential severe side effects.
Special: ECTRIMS 2024 – Personalized MS treatments, genetic risk factors and the benefits of early, effective therapies for women and children
This year, ECTRIMS 2024 in Copenhagen, Denmark, will once again bring together leading experts in multiple sclerosis (MS) from around the world. The prestigious conference is the premier event for researchers, physicians and healthcare professionals all working towards a common goal: improving quality of life through groundbreaking research and advances in the treatment of MS […]
Spezial: ECTRIMS 2024 – Personalisierte MS-Behandlungen, genetische Risikofaktoren und Vorteile früher, wirksamer Therapien für Frauen und Kinder
Dieses Jahr kommen auf der ECTRIMS 2024 in Kopenhagen, Dänemark, wieder führende Experten für Multiple Sklerose (MS) aus der ganzen Welt zusammen. Die renommierte Konferenz ist die wichtigste Veranstaltung für Forscher, Ärzte und medizinisches Fachpersonal, die alle auf ein gemeinsames Ziel hinarbeiten: die Verbesserung der Lebensqualität durch bahnbrechende Forschung und Fortschritte bei der Behandlung von […]
#078: Cladribine (Mavenclad, Leustat, Litak) for highly active MS
Cladribine (Mavenclad, Leustat, Litak) is an induction therapy the supresses the immun system and is used for highly active MS.
#268: S1P-Modulatoren – Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) für aktive RRMS und SPMS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#076: Alemtuzumab (Lemtrada, Campath) for highly active Multiple Sclerosis
Alemtuzumab (Lemtrada, Campath) is a DMT to treat highly active MS and has long-lasting effects and potential severe side effects.
#266: Natalizumab (Tysabri, Tyruko) für aktive schubförmig remittierende MS
Natalizumab (Tysabri, Tyruko) wird für aktive schubförmig remittierende MS eingesetzt als Infusion oder Spritze und wirkt sehr schnell.
#075: Decoding the EDSS Score. How It’s Measured and What It Means
The Expanded Disability Status Scale (EDSS) is a key tool used by neurologists to measure how Multiple Sclerosis (MS) affects your body. Understanding the EDSS can help you gain insight into your condition and assist in making informed decisions about your treatment. In this article, I’ll simplify the EDSS, explaining how it assesses eight key […]
#074: S1P Modulators – Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) for active RRMS & SPMS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.